The key to getting value from biopharmaceutical innovation is ensuring all drugs go generic without undue delay.

Sometimes drug companies make it difficult for generic competition through legal maneuvers known as "patent gaming." In other cases, scientifically complex drugs like gene therapies and some biologics that can't be copied could remain natural monopolies regardless of patents. The prices of drugs that cannot or will not go generic should be regulated once their patents expire to ensure society gets value for its investment in innovation.

‍

NPLB supports a framework that ensures all drugs go generic called Contractual Genericization

‍